Company profile
ASCENTAGE PHARMA GROUP INTERNATIONAL
NASDAQ:AAPGBiotechnology: Pharmaceutical Preparations
Drug pipeline (6)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| LISAFTOCLAX | phase3 | — | 12 | active |
| ALRIZOMADLIN | phase2 | — | 6 | active |
| Dasminapant | phase2 | — | 1 | unknown |
| OLVEREMBATINIB | phase2 | — | 5 | active |
| PELCITOCLAX | phase1_2 | — | 6 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (52)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04568265 | phase2 | unknown | 2020-06-03 | 2022-10-31 | Ascentage Pharma Group Inc. | A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B |
| NCT04275518 | phase1 | recruiting | 2020-07-06 | 2025-12-31 | Ascentage Pharma Group Inc. | A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. |
| NCT06389292 | phase3 | recruiting | 2024-06-11 | 2028-05-25 | Ascentage Pharma Group Inc. | A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia |
| NCT04126681 | phase2 | completed | 2019-10-21 | 2024-08-01 | Ascentage Pharma Group Inc. | A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase |
| NCT03883100 | phase2 | unknown | 2019-04-08 | 2024-04-01 | Ascentage Pharma Group Inc. | A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation |
FDA applications (0)
No records yet.